ABCD1 Gene Adrenoleukodystrophy x-linked Genetic Test
Are you concerned about Adrenoleukodystrophy (ALD)? DNA Labs UAE offers the ABCD1 Gene Adrenoleukodystrophy x-linked Genetic Test to help diagnose this rare genetic disorder. Read on to learn more about the test and its components, cost, symptoms, diagnosis, and more.
Test Details
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the nervous system and adrenal glands. It is caused by mutations in the ABCD1 gene, which provides instructions for making a protein that is essential for the breakdown of very long chain fatty acids (VLCFAs). When this protein is not functioning properly, VLCFAs build up in the body and cause damage to the myelin sheath that surrounds nerve cells in the brain and spinal cord.
ALD is an X-linked disorder, primarily affecting males. However, females can also be carriers of the gene mutation and may have mild symptoms or be asymptomatic.
NGS (next-generation sequencing) genetic testing is a type of genetic test that uses advanced technology to analyze multiple genes at once. This type of testing can identify mutations in the ABCD1 gene that cause ALD. NGS genetic testing for ALD may be recommended for individuals who have symptoms of the disorder, a family history of ALD, or are at risk of being carriers of the gene mutation. Testing may also be recommended for newborns as part of newborn screening programs in some states.
Early diagnosis and treatment of ALD is crucial to prevent or delay the onset of symptoms and slow the progression of the disease. Treatment options may include medications to reduce VLCFA levels, stem cell transplantation, and supportive care for symptoms such as seizures and adrenal insufficiency.
Test Name: ABCD1 Gene Adrenoleukodystrophy x-linked Genetic Test
- Components: DNA analysis for mutations in the ABCD1 gene
- Price: 3200.0 AED
- Sample Condition: Blood
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Neurological Disorders
- Doctor: Neurologist
- Test Department: Genetics
Pre Test Information
Before undergoing the ABCD1 Gene Adrenoleukodystrophy x-linked Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy, x-linked.
Genetic counseling can help individuals and families understand the inheritance pattern of ALD, assess their risk of being carriers, and make informed decisions about testing and treatment options.
Don’t delay in getting the necessary genetic testing for ALD. Contact DNA Labs UAE today to schedule an appointment and take control of your health.
| Test Name | ABCD1 Gene Adrenoleukodystrophy x-linked Genetic Test |
|---|---|
| Components | |
| Price | 3200.0 AED |
| Sample Condition | Blood |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ABCD1 Gene Adrenoleukodystrophy, x-linked NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy, x-linked |
| Test Details | Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the nervous system and adrenal glands. It is caused by mutations in the ABCD1 gene, which provides instructions for making a protein that is essential for the breakdown of very long chain fatty acids (VLCFAs). When this protein is not functioning properly, VLCFAs build up in the body and cause damage to the myelin sheath that surrounds nerve cells in the brain and spinal cord. ALD is an X-linked disorder, meaning that it primarily affects males. Females can also be carriers of the gene mutation and may have mild symptoms or be asymptomatic. NGS (next-generation sequencing) genetic testing is a type of genetic test that uses advanced technology to analyze multiple genes at once. This type of testing can identify mutations in the ABCD1 gene that cause ALD. NGS genetic testing for ALD may be recommended for individuals who have symptoms of the disorder, a family history of ALD, or are at risk of being carriers of the gene mutation. Testing may also be recommended for newborns as part of newborn screening programs in some states. Early diagnosis and treatment of ALD is important to prevent or delay the onset of symptoms and slow the progression of the disease. Treatment may include medications to reduce VLCFA levels, stem cell transplantation, and supportive care for symptoms such as seizures and adrenal insufficiency. |
